CRM 228 (T. Uchida, A. M. Pappenheimer, and R. Greany, J. Biol. Chem. 248:3838-3844, 1973), a mutant form of diphtheria toxin which completely lacks ADP-ribosyltransferase activity, contains five amino acid substitutions. The two amino acid changes that fall within the A chain of the toxin (G79D and E162K) were separately analyzed by substituting a variety of other amino acids at these sites. The substitution at position 79 (G79D) singularly appears to account for the loss of enzymatic activity found in CRM 228.
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Diphtheria toxin (DT; Mr, 58,342) is secreted by pathogenic strains of Corynebacterium diphtheriae. It is composed of an A and a B subunit; the A subunit (DTA) has ADP-ribosyltransferase (ADPRT) activity, catalyzing the transfer of ADP-ribose from NAD+ to a posttranslationally modified histidine residue, diphthamide, found in elongation factor 2 (12) . This results in the inhibition of protein synthesis and ultimately in the death of the intoxicated cell. The toxin B subunit (DTB) is responsible for binding to cell surface receptors and for mediating the translocation of the A subunit through the endosomal membrane into the cytosol.
Many of the initially identified structure-function relationships of the toxin were revealed by analysis of mutants produced by N-methyl-N'-nitro-N-nitrosoguanidine mutagenesis (29) . Toxins with altered function but with cross-reactivity against polyclonal anti-DT antibodies were generated. These cross-reacting materials (CRMs) generally fall into one of two groups: (a) those which are deficient in binding and/or translocation function (CRMs 30, 45, 228 [30, 31] , 107, 102, 103 [11, 20] , 9 [13] , and 1001 [7] ) and (b) those with altered enzymatic activity (CRM 197, 228, and 176 [24, 29, 30, 31] ). CRMs have not only provided useful information concerning the structurefunction relationships of the toxin but have also been used for a variety of purposes including immunotoxin construction (CRM 45 [6] , 107, 103, 102 [11, 16, 17] , and 9 [22] ) and genetic ablation studies (CRM 176 [3] ), and as protein carriers for carbohydrate antigens (CRM 197 [1] ).
Only two of these CRMs have no ADPRT activity: CRM 197 and CRM 228. CRM 197 has just one amino acid substitution (9) : glycine at position 52 is changed to glutamine (G52E) (nucleotides and amino acids are numbered according to reference 10). Although this mutation falls within the A chain of the toxin, there is evidence that the conformation of DTB is also altered as demonstrated by differences in toxin receptorbinding affinity (21) and lipid penetration (13, 25) . CRM 228 has a total of five substitutions, two within DTA (G79D and E162K) and three within DTB (S197G, P378S, and G431S) (18) . It has 15 to 20% of the binding activity of native DT and has no ADPRT activity (30, 31) . It was not known whether the lack of ADPRT activity can be attributed to just one or to both of the DTA substitutions. In an attempt to clarify this, the two affected DTA chain sites from CRM 228 (positions 79 and 162) were independently mutagenized; the native amino acid at each of these sites was substituted with a variety of other amino acids, and the relative enzymatic activities of the mutant proteins were compared.
Mutagenesis at position 79 or 162 was carried out with a PCR-based mutagenesis system as previously described (14) . Random nucleotide substitutions at positions 235 to 237 (encoding amino acid 79) or at positions 484 to 486 (encoding amino acid 162) enabled a variety of amino acids to be substituted at these sites ( Fig. 1) . PCR products were cloned into the Bluescript KS+ vector in a region downstream of the T7 RNA polymerase promoter, and Escherichia coli XL1 Blue was transformed with the recombinant library. The cloned region of the toxin gene encodes amino acids 1 to 193 corresponding to the enzymatically active form of DTA (32) , without DTB, so the construct is in compliance with the restrictions for cloning toxin genes (8) .
Plasmid DNA from the resulting colonies was isolated, transcribed, and translated in vitro with a coupled rabbit reticulocyte lysate-based system (Promega, Madison, Wis.), and L-[35S]methionine-labeled proteins were analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Clones producing a protein of the correct size were sequenced across the region spanning the mutagenized codon to determine the identity of the substituted amino acid. A total of 12 different amino acids were substituted in place of glycine at position 79, and a total of 10 were substituted at position 162. Toxins containing the individual amino acid substitutions found in CRM 228 (G79D or E162K) were among the mutants isolated.
Radiolabeled translation products were quantitated by trichloroacetic acid precipitation, and equal amounts of protein were compared by a cell-free ADP-ribosylation assay (16 To compare the overall toxicity of the G79D mutant, G79D DTA was combined with a native DTB by PCR-based techniques, and the resulting protein was expressed in vitro. The ability of the full-length mutant toxin (DT-G79D) to inhibit protein synthesis in Vero cells was compared with that of wild-type DT produced by the same method. The relative toxicity matched closely what would be predicted from the measured ADPRT activity: wild-type toxin was fully toxic, but the mutant was unable to inhibit protein synthesis at the maximum concentration produced in vitro. The protease sensitivities of these two full-length toxins were identical, demonstrating that the lack of toxicity of DT-G79D was not due to increased lability of the mutant (data not shown).
For consideration as a vaccine, a CRM should ideally contain multiple mutations, each independently capable of detoxifying the molecule. This is necessitated by the restrictions placed on the cloning of toxic proteins in E. coli (8) . It also eliminates the danger of an inactive mutant reverting to an enzymatically active form or of a second-site mutation restoring the original activity (19) . This work further clarifies the structure-function relationships of DTA and identifies the role of the G79D substitution in abolishing ADPRT activity. Mutations at this site, combined with mutations at some of the previously identified sites known to be important for ADPRT activity (e.g., G52 [30, 31] , H21 [14, 27] , Y65 [26] , and G148 [4, 28, 33] ), could be a potentially useful vaccine.
